Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
POU4F1
REST API REST API
Homo sapiens
POU4F1 is differentially expressed in 236 experiments: 71 organism parts: dorsal root ganglion, lung, ... (69 more);, 116 disease states: normal, Burkitt's lymphoma, ... (114 more);, 64 cell types 357 cell lines 15 compound treatments and 75 other conditions.
Synonyms RDC-1, BRN3A
Orthologs PO4F1_RAT (Rattus norvegicus)   F6TYG4_CIOIN (Ciona intestinalis)   BRN3_CHICK (Gallus gallus)   Pou4f1 (Mus musculus)   pou4f1 (Danio rerio)   acj6 (Drosophila melanogaster)   pou4f1 (Xenopus laevis)   (Compare orthologs)
Gene Ontology Term neuron differentiation, DNA binding, protein binding, synapse assembly, regulation of transcription, DNA-dependent, nuclear chromatin, transcription, DNA-dependent, regulation of neurogenesis, positive regulation of apoptosis, sequence-specific DNA binding, neuron projection, positive regulation of transcription from RNA polymerase II promoter, multicellular organismal development, nucleus, mesoderm development, nervous system development, axonogenesis, negative regulation of transcription from RNA polymerase II promoter, negative regulation of neuron apoptosis, peripheral nervous system neuron development, central nervous system neuron differentiation, proprioception involved in equilibrioception, cell migration in hindbrain, innervation, peripheral nervous system neuron differentiation, trigeminal nerve development, suckling behavior, neuron fate specification, habenula development, sequence-specific DNA binding transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription, sensory system development, ventricular compact myocardium morphogenesis, RNA polymerase II distal enhancer sequence-specific DNA binding, sequence-specific distal enhancer binding RNA polymerase II transcription factor activity
InterPro Term POU, Homeobox, POU_specific
UniProt Accession Q01851
Search EB-eye ENSG00000152192
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-MEXP-1251, E-MTAB-24, E-MTAB-25, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (38 experiments)

Factor Value U/D Experiments
A549
2
E-GEOD-3202, E-GEOD-6013
HCC1937
2
E-MTAB-37, E-MTAB-62
MDA468
2
E-MEXP-440, E-MTAB-62
SW480
2
E-MEXP-1014, E-GEOD-18005
T84
2
E-GEOD-1474, E-MTAB-37
primary culture
2
E-GEOD-2450, E-GEOD-1657
351 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-20677, E-GEOD-4219, E-GEOD-13987, E-TABM-34, ... (33 experiments)

Factor Value U/D Experiments
testis - germ cell
1
E-TABM-145
articular cartilage
1
E-MEXP-2488
n/a
1
E-MTAB-24
naive B cell
1
E-TABM-702
platelet
1
E-GEOD-2006
plasma cell
1
E-MEXP-2360
58 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-GEOD-1869, E-GEOD-1577, ... (48 experiments)

Factor Value U/D Experiments
dermatomyositis
2
E-GEOD-5370, E-GEOD-1551
Huntington's disease
2
E-GEOD-3790, E-AFMX-6
glioblastoma
2
E-GEOD-4290, E-MTAB-37
Burkitt's lymphoma
3
2
E-MTAB-37, E-GEOD-1880
Duchenne muscular dystrophy
3
2
E-GEOD-3307, E-GEOD-1004
alveolar rhabdomyosarcoma
2
E-MTAB-62, E-MEXP-121
110 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-3284, E-GEOD-412, E-GEOD-2803, E-GEOD-3720, ... (12 experiments)

Factor Value U/D Experiments
unknown
1
E-GEOD-7307
cigarette smoke
2
1
E-TABM-127
bacterial endotoxin
1
1
E-GEOD-3284
lipopolysaccharide
1
E-TABM-868
none
2
2
E-GEOD-412, E-TABM-868, E-GEOD-7307, E-GEOD-2803
control
1
1
31
E-GEOD-3284, E-GEOD-995
9 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-21653, E-GEOD-4922

Factor Value U/D Experiments
59
2
1
E-GEOD-21653
29
2
1
E-GEOD-3494
29 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, ... (8 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-1561, E-TABM-147, E-GEOD-21138, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-6431, E-MEXP-2340 ... (5 experiments)

Genotype
studied in E-GEOD-17476, E-TABM-321, E-TABM-868, E-GEOD-1153, E-GEOD-3790, ... (8 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-TABM-127, E-MEXP-1446, E-GEOD-10315, E-GEOD-837, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-GEOD-1926, E-TABM-15, E-GEOD-16363, E-GEOD-430, ... (31 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-980

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-17636, ... (7 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-1561, E-GEOD-4922

Tumor size
studied in E-GEOD-3494

Vehicle
studied in E-GEOD-5258

Processing time: 0.458 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM